DETECTION OF HUMAN CYTOMEGALOVIRUS INFECTIONS

对血液、尿液、咽喉和组织样本的监测 巨细胞病毒(CMV)的存在对于确定疾病的变化是重要的 人类免疫缺陷病毒感染患者的临床状况 (艾滋病毒1)。我们目前正在对患者进行实验性疗法的研究 HIV-1感染和艾滋病相关机会性感染(如巨细胞病毒) 确定原发感染的治疗是否会导致巨细胞病毒的变化 状态。磷甲酸钠(磷酸三钠)是一种抗病毒药物， 体外抗疱疹病毒(包括CMV)和HIV-1的活性 目前正在参加一项针对携带巨细胞病毒的艾滋病患者的随机试验 视网膜炎，测定磷甲酸钠联合AZT的毒性和疗效 联合治疗。似乎用磷甲酸钠立即治疗 在延缓CMV进展方面比延迟治疗更有效 视网膜炎。CMV败血症在1周内清除，病毒尿在2周内清除 诱导疗法。P24抗原水平的下降也被记录在案。 兼具抗CMV和抗HIV活性，磷甲酸钠可能成为重要的 艾滋病患者巨细胞病毒性视网膜炎的治疗。此外，还进行了一次审判 开始比较磷甲酸钠和更昔洛韦治疗艾滋病患者的疗效 患有巨细胞病毒视网膜炎。 在另一项单独的体外研究中，我们测试了两种药物，磷甲酸钠和 更昔洛韦单独及合用抗CMV病毒作用 效果。 研究发现，这两种药物联合使用具有协同作用。 对CMV复制的抑制作用。这些体外研究结果可能会导致 用这种药物组合治疗患者，允许使用减少的 个别药物的剂量，从而减少相关的药物 毒性，同时获得同等水平的抗病毒活性。

The monitoring of blood, urine, throat, and tissue specimens for the presence of cytomegalovirus (CMV) is important for determining changes in the clinical status of patients infected with human immunodeficiency virus (HIV 1). We are currently studying patients on experimental therapies for HIV 1 infection and AIDS related opportunistic infections (such as CMV) to determine if treatment of the primary infections results in changes in CMV status. Foscarnet (trisodium phosphonoformate) is an antiviral agent with in vitro activity against both herpesviruses (including CMV), and HIV 1. We are currently participating in a randomized trial of AIDS patients with CMV retinitis, to determine the toxicity and efficacy of foscarnet plus AZT combination treatment. It appears that immediate treatment with foscarnet is more effective than delayed therapy in postponing progression of CMV retinitis. CMV vinemia cleared in 1 week and viruria in 2 weeks on induction therapy. A decrease in p24 antigen levels was also documented. With both anti-CMV and anti-HIV activity, foscarnet may become an important treatment of CMV retinitis in patients with AIDS. In addition, a trial was initiated to compare foscarnet and ganciclovir treatments in AIDS patients with CMV retinitis. In a separate in vitro study, we tested two drugs, foscarnet and gancyclovir separately and in combination for their anti CMV virostatic effects. It was found that the combination of the two drugs has a synergistic inhibitory effect on CMV replication. These in vitro findings may result in patient treatment with this drug combination allowing for use of reduced doses of the individual drugs and thus reducing the drug associated toxicity while obtaining a comparable level of antiviral activity.